Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia results from the SPIRE randomized trials of bococizumab
ABCD PBi


Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia results from the SPIRE randomized trials of bococizumab

 
Disponível na Biblioteca:
  • FM - Fac. Medicina (OPI 29397 2018 )